NJ-based Amicus agreed to pay $100 million up front to buy privately-held Celenex, giving Amicus a portfolio of 10 experimental gene therapies.
The programs were developed at The Center for Gene Therapy at The Research Institute at Nationwide Children’s Hospital and The Ohio State University — Celenex was a spinoff from Nationwide Children’s Hospital.
The gene therapies are all for lysosomal storage disorders (LSDs), a focus for Amicus. The three lead programs are for Batten disease— a rare and life-threatening disorder.
Amicus could pay another $277 million in downstream payments if all Celenex’s programs successfully advance.
Read the Xconomy coverage
[javascriptSnippet]